Efficacy of memantine in PDD and DLB: An extension study including washout and open-label treatment

International Journal of Geriatric Psychiatry

Volumn 26, Issue 2, 2011, Pages 206-213

  Johansson, C ^a   Ballard, C ^b   Hansson, O ^a   Palmqvist, S ^a   Minthon, L ^a   Aarsland, D ^c   Londos, E ^a  

^a LUND UNIVERSITY   (Sweden)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

dementia; Lewy body disease; memantine; Parkinson's disease dementia

Indexed keywords

MEMANTINE; PLACEBO;

AGED; ANXIETY; ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PRACTICE; CONTROLLED STUDY; DEPRESSION; DIFFUSE LEWY BODY DISEASE; DIPLOPIA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL PRACTICE; NAUSEA; PARKINSON DISEASE; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE; VERTIGO;

AGED; AGED, 80 AND OVER; DOPAMINE AGENTS; DOUBLE-BLIND METHOD; FEMALE; GREAT BRITAIN; HUMANS; LEWY BODY DISEASE; MALE; MEMANTINE; NORWAY; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES; SWEDEN;

EID: 78651446247     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.2516     Document Type: Article

References (29)

1. Aarsland D, Ballard C, Walker Z, et al. 2009. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double- blind, placebo- controlled, multicentre trial. Lancet Neurol 8: 613 - 618.
2. Aarsland D, Zaccai J, Brayne C,. 2005. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 20: 1255 - 1263. (Pubitemid 41645899)
3. American Psychiatric Association (APA). 1994. Diagnostic and Statistical Manual of Mental Disorder, 4th edn. APA: Washington DC, USA.
4. Ballard C, McKeith I, Burn D, et al. 1997. The UPDRS scale as a means of identifying extrapyramidal signs in patients suffering from dementia with Lewy bodies. Acta Neurol Scand 96: 366 - 371.
5. Burns A, Gauthier S, Perdomo C,. 2007. Efficacy and safety of donepezil over 3 years: an open- label, multicentre study in patients with Alzheimer's disease. Int J Geriatr Psychiatry 22: 806 - 812.
6. Dalfo E, Albasanz JL, Martin M, Ferrer I,. 2004. Abnormal metabotropic glutamate receptor expression and signaling in the cerebral cortex in diffuse Lewy body disease is associated with irregular alpha- synuclein/phospholipase C (PLCbeta1) interactions. Brain Pathol 14: 388 - 398.
7. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD,. 2001. Open- label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 58: 427 - 433.
8. Emre M, Aarsland D, Albanese A, et al. 2004. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351: 2509 - 2518.
9. Ferri CP, Prince M, Brayne C, et al. 2005. Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112 - 2117.
10. Folstein MF, Folstein SE, McHugh PR,. 1975. "Mini- mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12: 189 - 198.
11. Geser F, Wenning GK, Poewe W, McKeith I,. 2005. How to diagnose dementia with Lewy bodies: state of the art. Mov Disord 20 (Suppl 12): S11 - 20.
12. Greenberg SM, Tennis MK, Brown LB, et al. 2000. Donepezil therapy in clinical practice: a randomized crossover study. Arch Neurol 57: 94 - 99.
13. Homma A, Imai Y, Tago H, et al. 2009. Long- term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52- week, open- label, multicenter, extension study in Japan. Dement Geriatr Cogn Disord 27: 232 - 239.
14. Leroi I, Brandt J, Reich SG, et al. 2004. Randomized placebo- controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 19: 1 - 8.
15. Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A,. 2009. Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord 24: 1217 - 1221.
16. Levin OS, Batukaeva LA, Smolentseva IG, Amosova NA,. 2009. Efficacy and safety of memantine in Lewy body dementia. Neurosci Behav Physiol 39: 597 - 604.
17. Lippa CF, Duda JE, Grossman M, et al. 2007. DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology 68: 812 - 819.
18. Lipton SA,. 2005. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low- affinity, uncompetitive antagonism. Curr Alzheimer Res 2: 155 - 165.
19. McKeith IG,. 2006. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. J Alzheimers Dis 9: 417 - 423.
20. McKeith I, Del Ser T, Spano P, et al. 2000. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double- blind, placebo- controlled international study. Lancet 356: 2031 - 2036.
21. McKeith IG, Dickson DW, Lowe J, et al. 2005. Diagnosis and management of dementia with Lewy bodies: third report of the DLB consortium. Neurology 65: 1863 - 1872.
22. Minett TS, Thomas A, Wilkinson LM, et al. 2003. What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry 18: 988 - 993.
23. Poewe W, Wolters E, Emre M, et al. 2006. Long- term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 21: 456 - 461.
24. Reisberg B, Doody R, Stoffler A, et al. 2003. Memantine in moderate- to- severe Alzheimer's disease. N Engl J Med 348: 1333 - 1341.
25. Ridha BH, Josephs KA, Rossor MN,. 2005. Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine. Neurology 65: 481 - 482.
26. Sabbagh MN, Hake AM, Ahmed S, Farlow MR,. 2005. The use of memantine in dementia with Lewy bodies. J Alzheimers Dis 7: 285 - 289.
27. Schneider LS, Olin JT, Doody RS, et al. 1997. Validity and reliability of the Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11 (Suppl 2): S22 - 32.
28. Tariot PN, Farlow MR, Grossberg GT, et al. 2004. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291: 317 - 324.
29. Thomas SJ, Grossberg GT,. 2009. Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging 4: 367 - 377.